Want to see IN:PPLPHARMA full AI Analyst Report?
Piramal Pharma Limited (PPLPHARMA) AI Stock Analysis
Piramal Pharma Limited
(NSE:PPLPHARMA)
Improving revenue, balance-sheet strength, and cash generation are the main positives. These are offset by recent losses, negative ROE, a negative P/E ratio, and mixed technical signals including overbought momentum and a negative MACD.
Piramal Pharma Limited (PPLPHARMA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 316.81B
- Dividend Yield
- 0.06%
- Average Volume (3M)
- 507.72K
- Price to Earnings (P/E)
- -151.4
- Beta (1Y)
- 1.21
- Revenue Growth
- 9.43%
- EPS Growth
- -767.49%
- Country
- India
- Employees
- 7,120
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Piramal Pharma Limited Business Overview & Revenue Model
Company Description
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilitie...
How the Company Makes Money
Piramal Pharma Limited makes money through three main revenue streams. (1) CDMO services: It earns service and manufacturing revenue by partnering with pharmaceutical and biotechnology companies to develop processes, scale up, and manufacture active...
Piramal Pharma Limited Financial Statement Overview
Summary
Revenue and equity have grown, while operating and free cash flow improved. However, profitability remains volatile, FY26 net income was negative, ROE was negative, and cash-flow coverage of net income was weak.
Income Statement
65PositiveBalance Sheet
72PositiveCash Flow
68Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.05B | 88.69B | 90.61B | 81.06B | 70.32B | 64.72B |
| Gross Profit | 32.91B | 23.83B | 54.89B | 48.48B | 40.32B | 37.91B |
| EBITDA | 10.81B | 9.96B | 16.49B | 13.67B | 8.94B | 12.60B |
| Net Income | -3.14B | -3.26B | 911.30M | 178.20M | -1.86B | 3.76B |
Balance Sheet | ||||||
| Total Assets | 0 | 179.65B | 156.78B | 153.12B | 145.23B | 127.97B |
| Cash, Cash Equivalents and Short-Term Investments | 13.55B | 13.55B | 5.21B | 5.02B | 6.60B | 3.79B |
| Total Debt | 0 | 56.75B | 48.56B | 47.10B | 56.37B | 41.28B |
| Total Liabilities | -81.63B | 98.02B | 75.52B | 74.00B | 77.49B | 61.00B |
| Stockholders Equity | 81.63B | 81.63B | 81.25B | 79.11B | 67.73B | 66.97B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 5.10B | 2.28B | 2.92B | -4.81B | -1.23B |
| Operating Cash Flow | 8.90B | 14.00B | 8.92B | 10.05B | 4.84B | 7.66B |
| Investing Cash Flow | -4.68B | -8.69B | -4.77B | -4.34B | -13.39B | -18.12B |
| Financing Cash Flow | -3.61B | 2.57B | -4.41B | -4.22B | 8.18B | 7.94B |
Piramal Pharma Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PPLPHARMA, the sentiment is Positive. The current price of 239.05 is above the 20-day moving average (MA) of 201.72, above the 50-day MA of 207.81, and above the 200-day MA of 177.10, indicating a bullish trend. The MACD of 4.75 indicates Negative momentum. The RSI at 73.03 is Negative, neither overbought nor oversold. The STOCH value of 92.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PPLPHARMA.
Piramal Pharma Limited Peers Comparison
Overall Rating
IN:CONCORDBIO67Neutral- IN:PPLPHARMA64Neutral
IN:DCAL56Neutral
IN:SYNGENE56Neutral
IN:BIOCON49Neutral
IN:JUBLINGREA46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:CONCORDBIO | 67Neutral | INR 130.28B | 46.20 | ― | 0.61% | 4.02% | -12.81% |
| IN:PPLPHARMA | 64Neutral | INR 318.26B | -151.42 | ― | 0.06% | 9.43% | -767.49% |
| IN:DCAL | 56Neutral | INR 22.76B | 33.34 | ― | ― | -20.86% | -34.51% |
| IN:SYNGENE | 56Neutral | INR 162.52B | 86.98 | ― | 0.31% | -5.99% | -60.30% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:BIOCON | 49Neutral | INR 573.10B | 103.47 | ― | 0.14% | 9.83% | 5.07% |
| IN:JUBLINGREA | 46Neutral | INR 89.05B | 25.14 | ― | 0.89% | 15.41% | 21.76% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:PPLPHARMA | Piramal Pharma Limited | 239.05 | 37.45 | 18.58% | |
| IN:BIOCON | Biocon Limited | 352.00 | -24.75 | -6.57% | |
| IN:CONCORDBIO | Concord Biotech Ltd. | 1245.30 | -214.11 | -14.67% | |
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 145.15 | -146.50 | -50.23% | |
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 559.05 | -127.98 | -18.63% | |
| IN:SYNGENE | Syngene International Ltd. | 402.60 | -253.29 | -38.62% |
Piramal Pharma Limited Corporate Events
Piramal Pharma Delivers Strong H1FY27 Performance and Upgrades Full-Year Outlook
Piramal Pharma Limited reported strong consolidated results for the second quarter and first half of FY27, with revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG and consumer healthcare...
Piramal Pharma Posts Strong H1 FY27 Growth and Upgrades Full-Year Outlook
Piramal Pharma reported robust unaudited consolidated results for the second quarter and first half of FY27, with revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG and consumer healthca...
Piramal Pharma Delivers Strong H1 FY27 and Upgrades Full-Year Outlook
Piramal Pharma Limited has reported strong financial performance for the second quarter and first half of FY27, with consolidated revenue from operations rising 28% year-on-year in Q2 and 23% in H1, driven by broad-based growth across CDMO, CHG, and...
Piramal Pharma Appoints Viral Gandhi as Chief Technology Officer
Piramal Pharma Limited has announced that its Board of Directors, following the recommendation of the Nomination and Remuneration Committee, has approved the appointment of Viral Gandhi as Chief Technology Officer and Senior Management Personnel effe...
Piramal Pharma to Appeal GST Order Confirming Rs 4.06 Crore Input Tax Credit Demand
Piramal Pharma Limited has disclosed that it received an Order-in-Original from the Additional Commissioner, CGST & Central Excise, Mumbai East, following a GST audit for financial years 2020-21 to 2022-23. The order disputes the eligibility of c...
Piramal Pharma earns ‘Leader’ ESG rating from independent assessor
Piramal Pharma Limited has received an Environment, Social and Governance rating of 67.1, placing it in the ‘Leader’ ESG band according to Niche Ninety Nine Capability and Certifications. The rating was communicated to the company by BSE...
Piramal Pharma Addresses FDA Observations at Morpeth Facility
Piramal Pharma Limited has announced that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Morpeth, U.K. facility from September 3 to September 11, 2026. The inspection resulted in a Form 483 containing seven observations, whic...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026